Trial Profile
A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Oct 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Lenalidomide (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; B-cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Post-transplant lymphoproliferative disorder; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; Primary-Effusion-Lymphoma; Sezary syndrome; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 28 Sep 2020 Status changed from active, no longer recruiting to completed.
- 19 Mar 2020 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 05 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.